Specificity of anti-Sm antibodies by ELISA for systemic lupus erythematosus: increased sensitivity of detection using purified peptide antigens

M FIELD, D G WILLIAMS, P CHARLES, AND R N MAINI

From the Clinical Immunology Division, Kennedy Institute of Rheumatology, Hammersmith, London

SUMMARY Sm antigen was purified by immunoaffinity chromatography using a murine monoclonal anti-Sm antibody and was confirmed to be free from contaminating polypeptides. This was then used to detect anti-Sm antibodies in patients' sera by enzyme linked immunosorbent assay (ELISA). Antibodies against Sm were detected in only 9/52 (17%) patients with systemic lupus erythematosus (SLE) by immunodiffusion, but 15/52 (29%) were positive for IgG anti-Sm antibodies by ELISA. The presence of anti-Sm antibodies remained disease specific despite the increase in sensitivity of this assay and validates its potential use for clinical application. There was no correlation between the presence of anti-Sm antibodies and any clinical features of SLE. In 23 renal biopsies a membranous component to the glomerulonephritis correlated with anti-Sm antibodies (p<0.05). Patients from West Africa, the Caribbean Islands, and Asia had a higher prevalence of anti-Sm antibodies than the local Caucasian population confirmed that the antigenic determinants reside on the protein moieties.

The aim of this study was to use a murine monoclonal anti-Sm antibody to obtain highly purified Sm antigen by affinity chromatography for use in an ELISA. Serum samples from patients with autoimmune diseases were analysed for the presence of anti-Sm antibodies to investigate their diagnostic specificity for SLE. The clinical features of all patients were analysed to assess whether the presence of anti-Sm antibodies predisposes to any specific disease manifestations.

Patients and methods

Sm was purified by a modified method of Buchanan et al. Affinity chromatography columns were made by coupling purified IgG to cyanogen bromide activated Sepharose beads (Pharmacia, Milton Keynes, Buckinghamshire). Rabbit thymus extract (Pelfreeze Biologicals, Arkansas, USA) was extracted (2% weight/volume) by sonication for one minute (Soniprep; MSE Scientific Instruments, Crawley, Sussex) in 0.1 M glycine containing 0.35 M NaCl, 10 mM trometamol (TRIS), and 0.1 mM phenylmethanesulphonyl fluoride (pH 7.4). The insoluble fraction was separated by centrifugation at 4000 g.

Accepted for publication 9 March 1988.
Correspondence to Dr M Field, Clinical Immunology Division, Kennedy Institute of Rheumatology, 6 Bute Gardens, Hammersmith, London W6 7DW.
The soluble fraction was initially applied to a column made with normal human IgG, and the drop through was sequentially passed down a column containing IgG from a patient with high titre monospecific anti-RNP antibody and then down the column made with the murine monoclonal anti-Sm antibody (KSm2). Each column was separated, washed, and eluted with 3 M guanidinium hydrochloride (Sigma, Poole, Dorset). Fractions with the highest optical density at 280 nm were pooled, dialysed against saline, and stored at 0°C. Each extraction yielded 1-1.5 mg of pure Sm antigen from 2 g of rabbit thymus extract.

**Polypeptide Analysis**

The purified protein antigens were analysed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) modified according to Williams et al. The separated proteins were stained with Coomassie blue (Fig. 1).

The Sm antigen was also screened by ELISA (which see) using two murine monoclonal antibodies directed against the 29, 28 kilodalton doublet (KSm5) or the 16 kilodalton (KSm2) components of the Sm antigen to ensure both proteins were present in the purified antigen.

**Anti-Sm Antibody Detection**

Purified Sm antigen (30 μg/ml) was coated onto ELISA plates (Nunc Immunoplume, Roskilde, Denmark), incubated at 4°C overnight, washed with PBS, and incubated with 2% casein (Fisons, Loughborough, Leicestershire) for 60 minutes at 37°C. The plate was then washed in 0.1% Tween in PBS (PBS/Tween) six times. All subsequent incubations and washes were performed similarly.

Each sample was assayed for anti-Sm antibodies by diluting 1:300 in 0.5% casein in PBS/Tween and applying 50 μl aliquots to individual wells. The plate was then incubated, washed, and bound IgG antibody detected using an antihuman (or antimouse when screening the monoclonal antibodies) IgG conjugate linked to alkaline phosphatase (Sigma, Poole, Dorset). The enzyme was detected with p-nitrophenyl phosphate (Substrate 104; Sigma, Poole, Dorset) and the optical density of each sample read at 405 nm in a Titertek multispan spectrophotometer (Flow Laboratories, Rickmansworth, Hertfordshire).

---

**Fig. 1** Sodium dodecyl sulphate-polyacrylamide gel electrophoresis of the eluates from the immunoaffinity columns; comparison with the molecular weight standards (mol. wt 94, 67, 43, 30, 20-1, 14-4 kilodaltons) in lane 1. Lane 2 shows the eluate from the normal IgG column. Lane 3 shows the eluate from the anti-RNP column with multiple bands including RNP bands at 67 and 33 and Sm bands at 29, 28, 16, and three bands at 13-11 kilodaltons. Lane 4 shows the purified Sm antigen from the monoclonal antibody and shows only the Sm specific bands.

**Fig. 2** The construction of the standard curve for the measurement of anti-Sm antibodies (for details see text).
The optical density of each sample was compared with a standard curve obtained by diluting a monospecific serum containing a high titre of anti-Sm antibodies. This was diluted threefold from 1:100 to 1:24 300 on each plate (Fig. 2). The lowest optical density obtained for a dilution of 1:24 300 was arbitrarily allocated a value of 3 ELISA units, that for the dilution of 1:8100—9 units, increasing up the dilution scale so that the value for the 1:300 dilution was ascribed 243 units. For those serum samples producing results above the standard curve a dilution was made and appropriate correction calculated to obtain the result for the standard dilution. All results were compared with those obtained in the laboratory by routine immunodiffusion.

PATIENTS
Serum was obtained from 52 patients with SLE over a three month period. Each was examined for features of SLE, in particular, skin, renal, and central nervous system dysfunction, and all fulfilled four or more criteria of the American Rheumatism Association. In addition, 53 patients with classical or definite rheumatoid arthritis, 20 with Sjögren's syndrome, 30 with systemic sclerosis, seven with polymyositis, 12 with polymyalgia rheumatica, and seven with osteoarthritis were analysed. Eight patients with multiple sclerosis and 30 healthy volunteers were also screened as diseased or normal controls.

Results

ANTIGEN ANALYSIS
The results from one representative ELISA confirmed the lack of contamination of Sm by other antigens (Fig. 3a). Serum containing anti-Sm antibody bound to the Sm antigens (1 and 2), whereas sera containing antibodies against SS-B and RNP did not. Normal human serum also failed to bind.

Screening with the monoclonal anti-Sm antibodies (Fig. 3b) demonstrated binding of both KSm5 and KSm2. There was no binding of 13B3/SW5, a monoclonal anti-SS-B antibody. Thus the purified Sm antigen was free from contamination and contained both the 29, 28 kilodalton doublet and the 16 kilodalton epitopes.

SDS-PAGE analysis of the eluate from the antibody columns confirmed the sequential purification of the Sm antigens. The normal IgG column eluate contained some bands purified non-specifically (Fig. 1, lane 2), but the anti-RNP column purified both the 67 and 33 kilodalton bands of RNP together with the 29, 28, 16, 13, and 11 kilodalton Sm polypeptides but also contained many contaminating bands (Fig. 1, lane 3). The anti-Sm
column eluate, however, contained solely the Sm proteins (Fig. 1, lane 4) and had no significant contaminating polypeptides.

**DETECTION OF ANTI-Sm ANTIBODIES**

In a single time point assay anti-Sm antibodies were detected in 15 patients with SLE (29%) and not in sera from patients with other connective tissue diseases or normal controls (Fig. 4). Comparison of the results obtained by ELISA and immunodiffusion demonstrated broad agreement between the two assays as the patients with higher titre by immunodiffusion tended to have a high titre by ELISA (Table 1). Six patients with SLE, however, had anti-Sm antibodies detectable solely by ELISA.

After a retrospective analysis of all 52 patients a further three had anti-Sm antibodies making a total of 18 (35%). Of the 45 women, 15 were positive (33%), as were three of the seven male patients (43%). Analysis by racial subgroups demonstrated seven patients positive out of 34 Caucasians (21%), eight of 11 Afro-Carribean patients (73%), and three of seven Asian patients (43%).

The presence of anti-Sm antibodies did not correlate with any features of SLE; in particular there was no correlation with skin, central nervous system, or renal disease. Of the 23 patients in whom renal biopsy was graded, however, the presence of anti-Sm antibodies was negatively associated with a pure diffuse proliferative glomerulonephritis (p<0.05) and positively associated with a membranous component to the glomerulonephritis (p<0.05) (Table 2).

**Discussion**

These data demonstrate that immunoaffinity chromatography with monoclonal antibodies produces large quantities of Sm antigen without significant

---

**Table 1** Anti-Sm antibodies detected by ELISA and immunodiffusion

<table>
<thead>
<tr>
<th>Patient No</th>
<th>ELISA (units)*</th>
<th>Immunodiffusion (dilution)†</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>52 650</td>
<td>&gt;1:64</td>
</tr>
<tr>
<td>2</td>
<td>1 647</td>
<td>Neg</td>
</tr>
<tr>
<td>3</td>
<td>1 273</td>
<td>1:4</td>
</tr>
<tr>
<td>4</td>
<td>630</td>
<td>1:1</td>
</tr>
<tr>
<td>5</td>
<td>531</td>
<td>Neg</td>
</tr>
<tr>
<td>6</td>
<td>282</td>
<td>1:4</td>
</tr>
<tr>
<td>7</td>
<td>78</td>
<td>1:4</td>
</tr>
<tr>
<td>8</td>
<td>63</td>
<td>1:1</td>
</tr>
<tr>
<td>9</td>
<td>62</td>
<td>1:4</td>
</tr>
<tr>
<td>10</td>
<td>58</td>
<td>1:4</td>
</tr>
<tr>
<td>11</td>
<td>46</td>
<td>Neg</td>
</tr>
<tr>
<td>12</td>
<td>20</td>
<td>1:1</td>
</tr>
<tr>
<td>13</td>
<td>15</td>
<td>Neg</td>
</tr>
<tr>
<td>14</td>
<td>10</td>
<td>Neg</td>
</tr>
<tr>
<td>15</td>
<td>6</td>
<td>Neg</td>
</tr>
</tbody>
</table>

*Normal value <3.
†Immunodiffusion was measured as a dilution of serum in which a precipitin could still be seen.

**Table 2** Renal biopsy results in patients with anti-Sm antibodies*

<table>
<thead>
<tr>
<th>Grade</th>
<th>Anti-Sm positive</th>
<th>Anti-Sm negative</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal (I)</td>
<td>0</td>
<td>0</td>
<td>NS</td>
</tr>
<tr>
<td>Mesangial (IIa, IIb)</td>
<td>3</td>
<td>3</td>
<td>NS</td>
</tr>
<tr>
<td>Focal and segmental (III)</td>
<td>2</td>
<td>5</td>
<td>NS</td>
</tr>
<tr>
<td>Diffuse proliferative (IV)</td>
<td>0</td>
<td>5</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Membranous (V)</td>
<td>5†</td>
<td>1</td>
<td>&lt;0.05</td>
</tr>
</tbody>
</table>

*Renal biopsy data were obtained from 23 of the patients with SLE and classified according to Appel et al.†
†Those with a membranous component included two with some evidence of proliferative change and one with a focal change.

---

**Fig. 4** The prevalence of anti-Sm antibodies in a variety of autoimmune and connective tissue diseases demonstrating their restriction to SLE. SLE=systemic lupus erythematosus; RA=rheumatoid arthritis; Scl=sclerosis; SS=Sjögren’s syndrome; PMS=polymyositis; PMR=polymyalgia rheumatica; OA=osteoarthritis; MS=multiple sclerosis; NHS=normal human serum.
contamination. The peptide composition of purified Sm compares well with that extracted by affinity chromatography, biochemical purification, and immunoprecipitation.

In an ELISA study for anti-Sm antibodies Maddison et al immunopurified Sm from RNAse digested thymus extract using human polyclonal antiserum. Anti-Sm antibodies were detected in patients with SLE but also in those with rheumatoid arthritis and other autoimmune diseases. Our data show that extraction by human polyclonal antiserum leads to copurification of non-specifically bound proteins (Fig. 1), which could result in false positive tests. These data demonstrate that the disease specificity of anti-Sm antibodies for SLE in sensitive ELISA assays depends on antigenic purity.

Pollard and Tan used biochemically purified antigen in an ELISA and found anti-Sm antibodies restricted to patients with SLE, but also in one patient with diabetes mellitus and a facial rash. The use of the monoclonal antibody to purify Sm antigen by affinity chromatography produces larger quantities of pure Sm than biochemical techniques, and its use in the ELISA shows that only patients with SLE have detectable IgG anti-Sm antibodies. Thus this method will provide an assay which could be readily used in clinical practice.

Comparison of ELISA and immunodiffusion showed six samples positive for anti-Sm by ELISA which were negative by immunodiffusion. Of these, four had anti-Sm antibodies in their serum detected by immunodiffusion either in previous or subsequent samples, implying that the ELISA is more sensitive than immunodiffusion. All four samples also had detectable anti-RNP antibodies by immunodiffusion, which may obscure anti-Sm precipitins.

Early studies suggested a link between anti-Sm antibodies and cerebral SLE, though these antibodies were not confirmed as markers for central nervous system disease in the lupus population as a whole. Comparison of the 52 patients in this study failed to delineate any association between anti-Sm antibodies and clinical characteristics of SLE. Similarly, no lupus features were ascribed to the presence of anti-Sm antibodies when using immunoprecipitation to detect these antibodies. These increasingly sensitive assays may well include a more representative sample of the lupus population in the positive group, hence removing any dissimilarity between populations.

A pure diffuse proliferative glomerulonephritis was not detected in any patient with anti-Sm antibodies, confirming results from two studies that compared the presence of renal disease with autoantibody profile. Winn et al found only one of 23 patients with anti-Sm antibodies with this severe proliferative renal change, and Venables et al showed that the presence of antibodies to soluble cellular antigens in general was commonly noted in association with a membranous glomerulonephritis. In murine models of SLE only the MRL strain develops anti-Sm antibodies, and these animals have a less severe glomerulonephritis than the NZB/W mice, which only have anti-DNA antibodies.

These studies demonstrate a higher incidence of anti-Sm antibodies than the 4–7% reported in the English studies and the 17% in the Indian population and are more in line with the prevalence in the USA lupus population. Nevertheless, the wide racial difference in the incidence of anti-Sm antibodies has been confirmed. Whether this is the result of genetic differences or the effect of some environmental factor in the initiation of the anti-Sm antibody response remains to be understood.

This work was supported by the Arthritis and Rheumatism Council.

References
Specificity of anti-Sm antibodies by ELISA for SLE 825


